In breast cancer, HER2 mutations vary in frequency from ~2% to 8% depending on disease stage and histology (higher in lobular)[7,10,11,13,14] and have been associated with poor prognosis[15,16]. This evidence concerns the gene ERBB2 and breast carcinoma.